Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices
Artificial Organs · 2023
DOI: 10.1111/aor.14565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2023. Verfasst von Amanda Sowder und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University of Kentucky Healthcare, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Stroke, Thrombosis, Heart Failure. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Background
The HeartMate3 left ventricular assist device (HM3 LVAD) has shown a low incidence of thrombosis, but bleeding risk is as high as 43%. We aim to describe the impact of lower international normalization ratio (INR) goal on clinical outcomes.
Methods
In February 2019, our tertiary care institution lowered INR goal in HM3 patients from manufacturer recommendations to 1.8–2.2 and retrospectively analyzed the data. Two cohorts were compared: patients with lower INR goal upon implant (De novo) and those with subsequently lowered INR goal (Adjusted). The Adjusted group also served as its own historical control. Both groups continued aspirin 81 milligrams daily per manufacturer recommendations. The primary outcomes were incidences of bleed and thrombosis events within 12 months. Secondary outcomes included survival free of disabling stroke or reoperation to remove or replace the device and Rosendaal time in therapeutic range (TTR) over 12 months.
Results
Thirty‐one patients were evaluated for inclusion with 26 meeting criteria. Within 12 months, incidence of bleeding events was 25% and 28.6% in the De novo and Adjusted groups, respectively. Incidence of thrombotic events within 12 months was 0% in the De novo group and 7.1% in the Adjusted group. Twelve‐month survival free of disabling stroke or reoperation to remove or replace the device was higher over 12 months for patients in the De novo group (91.7% vs. 78.6%). Median 12‐month TTR was 36%, which was primarily attributable to subtherapeutic deviations.
Conclusions
A lower INR goal may be safe when initiated De novo following implantation of the HM3. This study informs the need for larger prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, University of Kentucky Healthcare, Lexington, Kentucky, USA.
- Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
- Department of Cardiology, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
- Department of Cardiology, Indiana University Health, Indianapolis, Indiana, USA.
ORCID-Profile: Amanda Sowder
Zitieren
APA
Sowder, A., Ather, A., Birks, E., Kolodziej, A., Malyala, R., Sieg, A., Schadler, A., Unger, R., Guglin, M., & Kuan, W. (2023). Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices. Artificial Organs. https://doi.org/10.1111/aor.14565
Vancouver
Sowder A, Ather A, Birks E, Kolodziej A, Malyala R, Sieg A, et al. Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices. Artificial Organs. 2023. doi:10.1111/aor.14565
BibTeX
@article{Sowder2023,
author = {Sowder, Amanda and Ather, Ayesha and Birks, Emma and Kolodziej, Andrew and Malyala, Rajasekhar and Sieg, Adam and Schadler, Aric and Unger, Rachel and Guglin, Maya and Kuan, William},
title = {Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices},
journal = {Artificial Organs},
year = {2023},
doi = {10.1111/aor.14565}
}
EUVIMED